//
sign in
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
In the BTK inhibitor–naive setting, the BTK degrader tacabrutideg was safe with antitumor activity in CLL and other B-cell malignancies #EHA2026 #leusm #oncology Read more on cohort 1f of the phase 1 CaDAnCe-101 trial: www.onclive.com/view/tacabru...
9h
Tacabrutideg's safety profile was tolerable, and the drug had antitumor activity in BTK inhibitor–naive patients with CLL/SLL and other B-cell malignancies.
www.onclive.com
Tacabrutideg Is Tolerable and Shows Efficacy Signals Across BTK Inhibitor–Naive CLL and Other B-Cell Malignancies | OncLive
OncLive